Voiant, a leader in clinical trial imaging solutions, is announcing the acquisition of Voxeleron, a pioneering company in AI-driven ophthalmic image analysis. This strategic acquisition marks a significant advancement in Voiant’s mission to accelerate the development of innovative treatments for eye diseases.
Voiant’s extensive ophthalmic clinical trial expertise coupled with Voxeleron’ s cutting-edge technology will drive the next generation of imaging solutions for clinical research in ophthalmology. This synergy offers the best of both worlds: proven and trusted scientific and operational expertise in ophthalmic research coupled with AI-enhanced image analysis and technology. Our integrated platform now offers unmatched capabilities in ophthalmology, including advanced AI-driven insights for retinal and corneal imaging. This integration enables deeper clinical insights, improves data accuracy and accelerates the development of innovative treatments, hastening their delivery to patients in need.
Jim Primerano, CEO of Voiant, commented, “This acquisition is a strategic leap forward for Voiant. By combining our proven expertise with Voxeleron’s AI-powered innovation, we are setting new standards in ophthalmic clinical research. Our integrated platform will deliver deeper clinical insights, faster timelines, enhanced quality, and cost efficiencies, ultimately benefiting patients in need.”
Also Read: Cardiovascular Logistics and Cardiology Consultants of Philadelphia Announce Partnership to Expand Access to Cardiovascular Care in Southeastern Pennsylvania
Jonathan Oakley and Daniel Russakoff, Voxeleron co-founders, added, “We are excited to come together with Voiant. Our advanced AI image analysis capabilities, combined with Voiant’s extensive clinical trial expertise, will change the paradigm in the field of ophthalmology. Together, we will drive innovation and improve patient outcomes.”
Voiant will leverage its newly combined capabilities with continued investment to advance biomarker development and image analysis capabilities at an unparalleled pace. Our global investment in AI/ML development demonstrates our dedication to remaining at the forefront of clinical research innovation.
SOURCE: PRWeb